
  
    
      
        Background_NNP
        Fabry_NNP disease_NN is_VBZ an_DT X-_NNP linked_VBD disorder_NN resulting_VBG in_IN
        reduced_VBN activity_NN of_IN the_DT lysosomal_NN enzyme_NN α-galactosidase_JJ A_DT
        [_NN 1_CD 2_CD ]_NN ._. This_DT results_NNS in_IN the_DT systemic_JJ accumulation_NN of_IN
        D-_NNP galatosyl_NN conjugates_NNS ,_, particularly_RB globotriosylceramide_NN
        (_( Gb_NNP 3_LS )_) [_NN 3_CD 4_CD ]_NN ._. Although_IN the_DT disorder_NN is_VBZ heterogeneous_JJ ,_,
        patients_NNS suffer_VBP renal_JJ ,_, cardiovascular_JJ and_CC cerebrovascular_NN
        complications_NNS [_NN 4_CD ]_NN ._. Enzyme_NNP replacement_NN therapy_NN has_VBZ
        recently_RB shown_VBN to_TO have_VB an_DT effect_NN on_IN resting_VBG cerebral_JJ blood_NN
        flow_NN abnormalities_NNS and_CC on_IN other_JJ organ_NN systems_NNS functions_NNS [_NN 5_CD
        6_CD ]_NN ._. In_IN the_DT cerebrovascular_NN system_NN there_EX is_VBZ an_DT increased_VBN
        incidence_NN of_IN stroke_NN together_RB with_IN vessel_NN ectasia_NN [_NN 7_CD ]_NN ._.
        This_DT may_MD be_VB related_VBN to_TO the_DT progressive_JJ accumulation_NN of_IN
        storage_NN material_NN in_IN the_DT cerebral_JJ vessel_NN or_CC possibly_RB ,_, may_MD be_VB
        due_JJ to_TO an_DT abnormality_NN of_IN vessel_NN function_NN [_NN 8_CD 9_CD ]_NN ._. The_DT
        cerebrovascular_NN complications_NNS are_VBP distributed_VBN predominantly_RB
        in_IN the_DT posterior_NN circulation_NN with_IN a_DT progressive_JJ increase_NN
        over_IN time_NN in_IN the_DT posterior_NN distribution_NN of_IN small_JJ vessel_NN
        disease_NN as_IN found_VBN on_IN T_NN 
        2_CD -_: weighted_JJ images_NNS or_CC fluid_JJ attenuated_JJ
        inversion_NN recovery_NN (_( FLAIR_NNP )_) MR_NNP [_NN 7_CD 10_CD 11_CD ]_NN ._. It_PRP likely_JJ that_IN
        such_JJ high_JJ signal_NN lesions_NNS on_IN MR_NNP images_NNS represent_VBP ischemic_JJ
        small_JJ vessel_NN disease_NN ,_, however_RB ,_, there_EX are_VBP no_DT
        neuropathological-radiological_JJ correlative_JJ studies_NNS
        confirming_VBG this_DT assumption_NN ._. Since_IN ischemic_JJ brain_NN lesions_NNS
        are_VBP irreversible_JJ ,_, and_CC accumulate_VBP over_IN years_NNS ,_, demonstrating_VBG
        a_DT reduction_NN in_IN incidence_NN is_VBZ likely_JJ to_TO require_VB prolonged_JJ
        therapy_NN in_IN a_DT relatively_RB large_JJ cohort_NN of_IN patients_NNS following_VBG
        this_DT disease_NN end-point_JJ ._. Previously_RB ,_, in_IN Fabry_NNP disease_NN ,_, we_PRP
        have_VBP reported_VBN resting_VBG cerebral_JJ hyper-perfusion_JJ in_IN a_DT
        predominantly_RB vertebro-basilar_JJ distribution_NN together_RB with_IN
        abnormalities_NNS of_IN vascular_NN nitrotyrosine_NN staining_VBG ._. This_DT was_VBD
        reversed_VBN by_IN enzyme_NN replacement_NN therapy_NN [_NN 5_CD 10_CD ]_NN ._. The_DT
        current_JJ study_NN examines_VBZ the_DT cerebrovascular_NN system_NN in_IN Fabry_NNP
        disease_NN in_IN response_NN to_TO functional_JJ and_CC pharmacological_JJ
        activation_NN ._.
        We_PRP hypothesized_VBN that_IN the_DT cerebral_JJ vasculopathy_NN of_IN Fabry_NNP
        disease_NN is_VBZ associated_VBN with_IN abnormal_JJ cerebrovascular_NN
        responses_NNS ,_, and_CC furthermore_RB ,_, that_IN these_DT would_MD normalize_VB with_IN
        repeated_VBN intra-vascular_JJ infusion_NN of_IN α-galactosidase_JJ A_DT [_NN 5_CD 6_CD
        ]_NN ._. We_PRP compared_VBD the_DT functional_JJ cerebrovascular_NN responses_NNS in_IN
        Fabry_NNP disease_NN to_TO those_DT in_IN age_NN and_CC sex_NN matched_VBD controls_NNS
        using_VBG both_DT visual_JJ stimulation_NN and_CC acetazolamide_NN challenge_NN
        by_IN [_NN 15_CD O_NNP ]_NN H_NNP 
        2_CD O_NNP and_CC positron_NN emission_NN tomography_NN
        (_( PET_NNP )_) to_TO measure_VB rCBF_NN ._. The_DT patients_NNS were_VBD then_RB re-examined_JJ
        following_NN a_DT 6_CD -_: month_NN double-blind_JJ placebo-controlled_JJ trial_NN
        of_IN enzyme_NN replacement_NN therapy_NN (_( ERT_NNP )_) ._. Functional_NNP activation_NN
        by_IN visual_JJ stimulation_NN was_VBD chosen_VBN to_TO examine_VB the_DT
        vertebro-basilar_JJ diathesis_NNS of_IN Fabry_NNP disease_NN ._. Acetazolamide_NNP ,_,
        on_IN the_DT other_JJ hand_NN ,_, was_VBD hypothesized_VBN to_TO identify_VB areas_NNS of_IN
        decreased_VBD cerebral_JJ perfusion_NN following_VBG maximal_NN cerebral_JJ
        vasodilation_NN in_IN Fabry_NNP disease_NN compared_VBN to_TO controls_NNS ._. Such_JJ an_DT
        abnormality_NN ,_, if_IN present_JJ ,_, might_MD then_RB be_VB used_VBN to_TO assess_VB the_DT
        therapeutic_JJ efficacy_NN of_IN enzyme_NN replacement_NN therapy_NN ._.
        We_PRP define_VB our_PRP$ usage_NN of_IN the_DT term_NN cerebral_JJ 
        vasomotor_NN reserve_NN as_IN (_( ΔCBF_NN 
        res_NNS )_) the_DT CBF_NNP response_NN at_IN 20_CD or_CC 30_CD
        minutes_NNS post-acetazolamide_JJ challenge_NN minus_CC the_DT resting_VBG CBF_NNP
        for_IN each_DT subject_NN ._. We_PRP define_VB cerebral_JJ 
        vascular_NN reactivity_NN as_IN the_DT functional_JJ
        CBF_NNP response_NN to_TO a_DT stimulus_NN minus_CC the_DT resting_VBG CBF_NNP (_( ΔCBF_NN 
        react_VB )_) while_IN the_DT maximal_NN response_NN to_TO
        acetazolamide_NN challenge_NN provides_VBZ an_DT index_NN of_IN the_DT
        cerebrovascular_NN capacity_NN ._. The_DT CBF_NNP response_NN curve_NN to_TO
        acetazolamide_NN can_MD be_VB considered_VBN like_IN a_DT high_JJ pass_NN filter_NN
        with_IN an_DT onset_NN time_NN constant_JJ to_TO a_DT steady_JJ state_NN τ_NN 
        1_CD and_CC an_DT offset_VBN time_NN constant_JJ of_IN τ_NN 
        2_CD ._. Alteration_NNP and_CC prolongation_NN of_IN τ_NN 
        2_CD will_MD correspond_VB to_TO 
        prolonged_JJ cerebral_JJ vascular_NN response_NN
        time_NN ._. An_DT important_JJ concept_NN of_IN a_DT high_JJ pass_NN filter_NN is_VBZ
        that_IN the_DT system_NN response_NN is_VBZ dependent_JJ on_IN both_DT the_DT resistive_JJ
        (_( R_NN )_) and_CC capacitative_JJ (_( C_NNP )_) elements_NNS ._. Hence_RB ,_, the_DT steady_JJ state_NN
        value_NN as_RB well_RB as_IN time_NN constants_NNS τ_NN 
        1_CD and_CC τ_NN 
        2_CD depend_VB on_IN both_DT the_DT R_NN and_CC C_NNP components_NNS ._.
        Therefore_RB the_DT value_NN of_IN ΔCBF_NN 
        res_NNS also_RB depends_VBZ on_IN the_DT RC_NNP component_NN of_IN
        the_DT cerebral_JJ vascular_NN system_NN so_IN that_IN if_IN there_EX is_VBZ an_DT
        increased_VBN R_NN component_NN then_RB ΔCBF_NN 
        res_NNS will_MD be_VB reduced_VBN ,_, a_DT situation_NN seen_VBN in_IN
        cerebral_JJ vaso-occlusive_JJ disease_NN ._. If_IN on_IN the_DT other_JJ hand_NN the_DT
        RC_NNP components_NNS are_VBP approximately_RB equal_JJ in_IN the_DT comparison_NN
        groups_NNS ,_, similar_JJ steady_JJ state_NN values_NNS of_IN CBF_NNP and_CC ΔCBF_NN 
        res_NNS values_NNS will_MD be_VB seen_VBN ._. The_DT magnitude_NN
        of_IN the_DT steady_JJ state_NN response_NN by_IN itself_PRP gives_VBZ an_DT index_NN of_IN
        the_DT cerebrovascular_NN capacitative_JJ component_NN (_( C_NNP )_) ._.
      
      
        Patients_NNS and_CC Methods_NNP
        
          Patients_NNS
          The_DT methodology_NN for_IN this_DT work_NN has_VBZ been_VBN described_VBN in_IN
          detail_NN [_NN 5_CD ]_NN ._. Twenty-six_NNP male_JJ hemizygote_NN patients_NNS with_IN
          Fabry_NNP disease_NN (_( age_NN range_NN 19_CD -_: 48_CD ,_, mean_VBP age_NN 33_CD ._. 7_CD ±_NN 8_CD ._. 1_CD
          years_NNS )_) and_CC 10_CD control_NN subjects_NNS (_( age_NN range_NN 21_CD -_: 48_CD years_NNS ,_,
          mean_VB age_NN 33_CD ._. 4_LS ±_NN 9_CD ._. 7_CD years_NNS )_) were_VBD enrolled_VBN in_IN the_DT study_NN ._.
          The_DT Institutional_NNP Review_NNP Board_NNP of_IN the_DT National_NNP Institute_NNP
          of_IN Neurological_NNP Disorders_NNP and_CC Stroke_NNP and_CC the_DT NIH_NNP
          Radiation_NNP Safety_NNP Committee_NNP approved_VBD the_DT study_NN and_CC all_DT
          patients_NNS and_CC healthy_JJ volunteers_NNS gave_VBD their_PRP$ written_VBN and_CC
          informed_VBN consent_NN ._. All_DT patients_NNS recruited_VBN to_TO this_DT study_NN
          had_VBD neuropathic_JJ pain_NN (_( main_JJ inclusion_NN criterion_NN )_) no_DT focal_JJ
          or_CC global_JJ neurological_JJ deficits_NNS and_CC normal_JJ clotting_VBG
          function_NN ._. Radiological_NNP evidence_NN consistent_JJ with_IN small_JJ
          vessel_NN disease_NN was_VBD noted_VBN primarily_RB on_IN the_DT FLAIR_NNP MRI_NNP as_IN
          hyper-intense_JJ signal_NN areas_NNS in_IN 10_CD patients_NNS ._. Four_CD patients_NNS
          had_VBD one_CD lesion_NN on_IN FLAIR_NNP imaging_NN ,_, three_CD patients_NNS had_VBD 3_CD
          lesions_NNS and_CC three_CD patients_NNS had_VBD >_NN 3_CD lesions_NNS ._. There_EX was_VBD
          no_DT significant_JJ progression_NN of_IN the_DT lesion_NN burden_NN over_IN the_DT
          6_CD -_: month_NN trial_NN period_NN ._. No_DT significant_JJ radiological_JJ
          abnormality_NN was_VBD found_VBN on_IN magnetic_JJ resonance_NN angiography_NN
          in_IN the_DT Fabry_NNP patients_NNS with_IN no_DT report_NN of_IN dolichoectasia_NN ._.
          One_CD patient_NN ,_, randomized_JJ to_TO the_DT placebo_NN study_NN arm_NN ,_,
          withdrew_VBD from_IN the_DT study_NN for_IN personal_JJ reasons_NNS and_CC three_CD
          further_JJ patients_NNS (_( 1_CD from_IN the_DT ERT_NNP group_NN and_CC 2_CD from_IN the_DT
          placebo_NN group_NN )_) declined_VBD the_DT follow-up_JJ acetazolamide_NN
          challenge_NN arm_NN of_IN the_DT study_NN at_IN completion_NN of_IN the_DT trial_NN ._. A_DT
          further_JJ patient_NN had_VBD suffered_VBN a_DT lacunar_NN infarct_NN ten_CD years_NNS
          prior_RB to_TO commencement_NN of_IN the_DT present_JJ study_NN ._. The_DT
          double-blind_JJ placebo-controlled_JJ randomized_JJ trial_NN of_IN ERT_NNP
          consisted_VBD of_IN intravenous_JJ infusions_NNS of_IN α_NN galactosidase_NN A_DT (_(
          
          Replagal_NNP ™_NN )_) every_DT two_CD weeks_NNS
          (_( Transkaryotic_NNP Therapies_NNP ,_, Inc_NNP ._. ,_, Cambridge_NNP ,_, MA_NNP )_) with_IN
          fourteen_CD patients_NNS receiving_VBG ERT_NNP and_CC twelve_CD placebo_NN for_IN
          six_CD months_NNS ._.
        
        
          PET_NNP Procedure_NNP
          PET_NNP was_VBD performed_VBN with_IN a_DT Scanditronix_NNP PC_NNP 2048_CD -_: 15_CD B_NNP
          tomograph_NN (_( tranverse_NN resolution_NN of_IN ~_NN 6_CD ._. 5_LS mm_NN )_) ._. A_DT radial_NN
          arterial_NN line_NN was_VBD placed_VBN in_IN all_DT participants_NNS for_IN
          measurement_NN of_IN the_DT [_NN 15_CD O_NNP ]_NN H_NNP 
          2_CD O_NNP input_NN function_NN and_CC arterial_NN blood_NN
          gases_NNS ._. Subjects_NNP were_VBD aligned_VBN in_IN the_DT scanner_NN with_IN slices_NNS
          parallel_JJ to_TO the_DT orbital-meatal_JJ line_NN with_IN at_IN least_JJS one_CD
          slice_NN obtained_VBN within_IN the_DT posterior_NN fossa_NN ._. The_DT head_NN was_VBD
          restrained_VBN with_IN a_DT thermoplastic_JJ facemask_NN ._. Transmission_NNP
          scans_NNS were_VBD obtained_VBN with_IN a_DT rotating_VBG 68_CD Ge_NNP /_NN 68_CD Ga_NNP pin_VB
          source_NN ,_, and_CC were_VBD used_VBN to_TO correct_VB emission_NN scans_VBZ for_IN
          attenuation_NN ._.
          Emission_NNP scans_VBZ (_( four_CD minutes_NNS duration_NN )_) were_VBD obtained_VBN
          after_IN intravenous_JJ injection_NN of_IN 35_CD mCi_NN of_IN [_NN 15_CD O_NNP ]_NN H_NNP 
          2_CD O_NNP and_CC were_VBD begun_VBN automatically_RB
          following_VBG arrival_NN of_IN radioactivity_NN in_IN the_DT brain_NN ._. Each_DT
          study_NN commenced_VBD with_IN a_DT sham_NN scan_VB in_IN order_NN to_TO acclimatize_NN
          the_DT subject_NN to_TO scanning_VBG procedure_NN which_WDT was_VBD followed_VBN by_IN
          two_CD resting_VBG cerebral_JJ blood_NN flow_NN scans_VBZ during_IN which_WDT the_DT
          subject_JJ maintained_VBN eye_NN closure_NN ._. Two_CD scans_VBZ during_IN visual_JJ
          stimulation_NN were_VBD also_RB performed_VBN 10_CD minutes_NNS apart_RB ._. During_IN
          visual_JJ activation_NN the_DT subjects_NNS were_VBD asked_VBN to_TO focus_VB on_IN a_DT
          black_NN and_CC white_JJ pattern_NN reversal_NN screen_NN ._. The_DT reversal_NN
          frequency_NN was_VBD 8_CD Hz_NNP ._. This_DT stimulus_NN frequency_NN is_VBZ known_VBN to_TO
          induce_VB the_DT maximal_NN change_NN in_IN the_DT striate_NN cortex_NN blood_NN
          flow_NN [_NN 12_CD ]_NN ._. The_DT visual_JJ stimulus_NN was_VBD commenced_VBD ~_NN 15_CD
          seconds_NNS before_IN radioactivity_NN reached_VBD the_DT head_NN ._. Following_VBG
          the_DT visual_JJ activation_NN scans_VBZ ,_, intravenous_JJ acetazolamide_NN
          was_VBD injected_VBN at_IN a_DT dose_NN of_IN 15_CD mg_NN /_NN kg_NN body_NN weight_NN and_CC two_CD
          further_JJ scans_NNS were_VBD obtained_VBN 20_CD and_CC 30_CD minutes_NNS later_RB ._.
        
        
          Data_NNP Analysis_NNP
          The_DT time_NN shift_NN between_IN arterial_NN blood_NN and_CC brain_NN data_NNS
          was_VBD determined_VBN by_IN aligning_VBG the_DT scanner_NN count_NN rate_NN data_NNS
          (_( sampled_VBN at_IN ~_NN 1_CD Hz_NNP )_) to_TO the_DT blood_NN data_NN with_IN the_DT slice_NN count_NN
          data_NNS fitted_JJ to_TO a_DT one-tissue_JJ compartment_NN two-parameter_JJ
          model_NN ._. The_DT CBF_NNP images_NNS were_VBD constructed_VBN from_IN a_DT
          pixel-by-pixel_JJ least_JJS square_JJ fit_NN for_IN blood_NN flow_NN and_CC
          partition_NN coefficient_NN [_NN 13_CD 14_CD ]_NN ._. The_DT MRI_NNP T_NN 1_CD template_NN was_VBD
          downloaded_JJ from_IN the_DT Montreal_NNP Neurological_NNP Institute_NNP
          http_NN :_: /_NN /_NN www_NN ._. bic_JJ ._. mni_NN ._. mcgill_NN ._. ca_MD /_NN [_NN 15_CD ]_NN ._. This_DT served_VBD as_IN a_DT
          template_NN for_IN spatially_RB registering_VBG the_DT PET_NNP data_NN ._. Prior_RB to_TO
          spatial_NN registration_NN the_DT MRI_NNP template_NN and_CC PET_NNP rCBF_NN images_NNS
          were_VBD resampled_JJ to_TO 256_CD ×_NN 256_CD ×_NN 90_CD ,_, 0_CD ._. 9375_CD mm_NN isotropic_JJ voxels_NNS ._.
          Pixel-by-pixel_NNP averaging_NN of_IN the_DT replicated_VBN visual_JJ
          activation_NN PET_NNP scans_VBZ was_VBD performed_VBN ._. Spatial_NNP registration_NN
          of_IN the_DT PET_NNP images_NNS and_CC T_NN 1_CD MRI_NNP template_NN was_VBD performed_VBN using_VBG
          SPM_NNP 99_CD http_NN :_: /_NN /_NN www_NN ._. fil_NN ._. ion_NN ._. ucl_NN ._. ac_NN ._. uk_NN /_NN spm_NN /_NN spm_NN 99_CD ._. html_NN [_NN 16_CD ]_NN
          ._.
          The_DT analysis_NN is_VBZ divided_VBN into_IN a_DT comparison_NN of_IN the_DT
          baseline_JJ Fabry_NNP group_NN with_IN the_DT control_NN group_NN and_CC the_DT
          comparison_NN of_IN the_DT ERT_NNP group_NN with_IN the_DT placebo_NN group_NN ._. A_DT
          straight_JJ comparison_NN was_VBD made_VBN between_IN the_DT control_NN group_NN
          and_CC the_DT baseline_NN (_( time_NN zero_CD )_) Fabry_NNP group_NN visual_JJ and_CC
          acetazolamide_NN co-registered_JJ PET_NNP data_NNS using_VBG SPM_NNP 99_CD allowing_VBG
          appropriate_JJ multiple_JJ comparisons_NNS analyses_NNS ._. In_IN order_NN to_TO
          isolate_VB a_DT potential_JJ treatment_NN effect_NN following_VBG ERT_NNP ,_, a_DT
          mixed_JJ statistical_JJ model_NN was_VBD used_VBN ._. This_DT analysis_NN of_IN
          variance_NN model_NN divides_VBZ the_DT total_JJ variance_NN into_IN fixed_VBN and_CC
          random_JJ effects_NNS with_IN the_DT treatment_NN effect_NN attributable_JJ to_TO
          the_DT fixed_VBN effect_NN ._. A_DT two-step_JJ approach_NN was_VBD adopted_VBN ._. The_DT
          first_JJ allowing_VBG isolation_NN of_IN the_DT fixed_VBN effect_NN by_IN forming_VBG
          subtraction_NN images_NNS for_IN each_DT patient_NN by_IN subtracting_VBG the_DT
          pre-trial_JJ response_NN from_IN the_DT post-trial_JJ response_NN forming_VBG a_DT
          contrast_NN image_NN ._. The_DT second_RB consisted_VBD of_IN direct_JJ comparison_NN
          of_IN the_DT ERT_NNP and_CC non-_NN ERT_NNP subgroups_NNS contrast_VBP images_NNS ._. In_IN this_DT
          way_NN ,_, the_DT attributable_JJ treatment_NN effects_NNS were_VBD compared_VBN for_IN
          the_DT analysis_NN of_IN the_DT visual_JJ activation_NN and_CC acetazolamide_NN
          responses_NNS on_IN a_DT patient-by-patient_JJ basis_NN ._. This_DT gave_VBD for_IN
          each_DT patient_NN a_DT difference_NN image_NN representing_VBG an_DT
          independent_JJ estimate_NN of_IN each_DT subject_NN 's_POS response_NN to_TO visual_JJ
          activation_NN and_CC acetazolamide_NN after_IN ERT_NNP or_CC placebo_NN ._.
          Statistical_NNP parametric_JJ maps_NNS (_( SPM_NNP {_( t_NN }_) )_) were_VBD then_RB calculated_VBN
          on_IN the_DT spatially_RB registered_VBN PET_NNP images_NNS by_IN obtaining_VBG a_DT
          set-level_JJ statistic_NN of_IN p_NN <_NN 0_CD ._. 05_CD after_IN setting_VBG the_DT
          voxel_NN threshold_NN at_IN p_NN <_NN 0_CD ._. 05_CD or_CC less_JJR and_CC the_DT cluster_NN
          extent_NN at_IN 1024_CD or_CC greater_JJR ._. The_DT cluster_NN extent_NN threshold_NN
          represents_VBZ ~_NN 1_CD ._. 0_CD cm_NN 3_CD of_IN brain_NN tissue_NN ._. The_DT set-level_JJ
          statistic_NN represents_VBZ the_DT statistical_JJ significance_NN of_IN the_DT
          compared_VBN data_NN volumes_NNS ._. All_DT the_DT p-values_JJ given_VBN in_IN the_NNP
          '_POS Results_NNS '_POS section_NN are_VBP the_DT set-level_JJ statistic_NN ._.
          In_IN order_NN to_TO characterize_VB the_DT visual_JJ activation_NN
          response_NN further_RBR ,_, a_DT specific_JJ region_NN of_IN interest_NN (_( ROI_NNP )_) was_VBD
          used_VBN that_WDT included_VBD Brodmann_NNP areas_NNS 17_CD ,_, 18_CD and_CC 19_CD as_IN
          determined_VBN from_IN the_DT Talairach-_NNP Tournoux_NNP electronic_JJ brain_NN
          atlas_NNS [_NN 17_CD ]_NN ._. The_DT visual_JJ ROI_NNP was_VBD derived_VBN from_IN T_NN 1_CD MRI_NNP
          template_NN which_WDT was_VBD then_RB used_VBN to_TO mask_NN the_DT SPM_NNP registered_VBD
          CBF_NNP images_NNS prior_RB to_TO calculation_NN of_IN the_DT visual_JJ CBF_NNP
          responses_NNS ._. The_DT mean_JJ visual_JJ cortex_NN CBF_NNP and_CC global_JJ CBF_NNP
          values_NNS were_VBD calculated_VBN on_IN a_DT pixel-by-pixel_JJ basis_NN after_IN
          setting_VBG a_DT CBF_NNP threshold_NN value_NN of_IN 10_CD ._. 0_CD ml_NN /_NN min_NN /_NN 100_CD g_SYM of_IN
          tissue_NN below_IN which_WDT the_DT pixels_NNS were_VBD excluded_VBN from_IN
          calculation_NN ._. This_DT CBF_NNP level_NN represents_VBZ the_DT lower_JJR limit_NN of_IN
          CNS_NNP tissue_NN viability_NN ._. The_DT ROI_NNP consisted_VBD of_IN both_DT gray_JJ and_CC
          white_JJ matter_NN areas_NNS associated_VBN with_IN the_DT visual_JJ cortex_NN and_CC
          association_NN areas_NNS ._.
        
      
      
        Results_NNS
        
          Visual_NNP Activation_NNP Studies_NNPS (_( Table_NNP 1_LS )_)
          Mean_VB absolute_JJ CBF_NNP in_IN the_DT visual_JJ cortex_NN was_VBD
          significantly_RB greater_JJR in_IN Fabry_NNP patients_NNS during_IN visual_JJ
          stimulation_NN compared_VBN to_TO the_DT control_NN group_NN (_( p_NN =_SYM 0_CD ._. 002_CD )_) ._.
          The_DT visual_JJ CBF_NNP reactivity_NN (_( ΔCBF_NN 
          react_VB )_) following_VBG visual_JJ stimulation_NN
          was_VBD calculated_VBN in_IN each_DT subject_NN by_IN subtracting_VBG the_DT visual_JJ
          cortex_NN resting_VBG cerebral_JJ blood_NN flow_NN from_IN the_DT mean_JJ visual_JJ
          activation_NN CBF_NNP ._. No_DT significant_JJ difference_NN was_VBD found_VBN in_IN
          the_DT visual_JJ area_NN ΔCBF_NN 
          react_VB between_IN patients_NNS and_CC controls_NNS ._.
          After_IN enzyme_NN replacement_NN therapy_NN there_EX was_VBD no_DT significant_JJ
          change_NN in_IN the_DT mean_JJ absolute_JJ CBF_NNP response_NN to_TO visual_JJ
          stimulation_NN over_IN the_DT visual_JJ area_NN (_( p_NN =_SYM 0_CD ._. 184_CD )_) ,_, or_CC in_IN ΔCBF_NN 
          react_VB compared_VBN to_TO placebo_NN (_( p_NN =_SYM
          0_CD ._. 629_CD )_) ._.
        
        
          Acetazolamide_NNP Challenge_NNP Studies_NNPS -_: global_JJ CBF_NNP (_( Table_NNP
          2_LS )_)
          Resting_NNP and_CC post-acetazolamide_JJ global_JJ CBF_NNP values_NNS were_VBD
          not_RB significantly_RB different_JJ between_IN the_DT control_NN group_NN and_CC
          the_DT untreated_JJ patient_NN group_NN for_IN either_DT the_DT twenty-minute_JJ
          or_CC thirty-minute_JJ time_NN point_NN ._. Following_VBG the_DT enzyme_NN
          replacement_NN trial_NN ,_, no_DT significant_JJ change_NN in_IN the_DT global_JJ
          CBF_NNP was_VBD found_VBN at_IN the_DT 20_CD -_: minutes_NNS post-acetazolamide_JJ time_NN
          point_NN in_IN the_DT ERT_NNP group_NN compared_VBN to_TO the_DT placebo_NN group_NN ,_,
          however_RB ,_, the_DT resting_VBG global_JJ CBF_NNP in_IN the_DT ERT_NNP group_NN was_VBD
          significantly_RB decreased_VBN (_( p_NN =_SYM 0_CD ._. 026_CD )_) ._. A_DT significant_JJ
          reduction_NN (_( p_NN =_SYM 0_CD ._. 036_CD )_) in_IN the_DT global_JJ CBF_NNP was_VBD found_VBN
          30_CD -_: minutes_NNS post-acetazolamide_JJ in_IN the_DT ERT_NNP group_NN compared_VBN
          to_TO the_DT placebo_NN group_NN ._. No_DT difference_NN in_IN the_DT global_JJ
          vasomotor_NN reserve_NN was_VBD found_VBN between_IN Fabry_NNP patients_NNS and_CC
          controls_NNS before_IN or_CC following_VBG ERT_NNP ._.
        
        
          Regional_NNP SPM_NNP Analysis_NNP of_IN Visual_NNP Activation_NNP and_CC
          Acetazolamide_NNP Challenge_NNP Studies_NNPS
          There_EX was_VBD a_DT significantly_RB increased_VBN blood_NN flow_NN in_IN the_DT
          Fabry_NNP patients_NNS during_IN visual_JJ stimulation_NN compared_VBN to_TO
          controls_NNS (_( Figure_NN 1_CD ,_, p_NN <_NN 0_CD ._. 001_CD )_) ._. The_DT increased_VBN rCBF_NN was_VBD
          found_VBN predominantly_RB in_IN the_DT posterior_NN circulation_NN area_NN and_CC
          visual_JJ cortex_NN but_CC some_DT voxels_NNS increases_NNS in_IN rCBF_NN were_VBD
          found_VBN in_IN the_DT anterior_NN circulation_NN ._. No_DT rCBF_NN voxels_NNS were_VBD
          found_VBN to_TO be_VB significantly_RB greater_JJR in_IN the_DT control_NN group_NN
          compared_VBN to_TO the_DT Fabry_NNP group_NN (_( data_NNS not_RB shown_VBN )_) ._. Restriction_NNP
          of_IN the_DT rCBF_NN analysis_NN to_TO Talairach-defined_NNP visual_JJ cortex_NN
          ROI_NNP showed_VBD no_DT significant_JJ difference_NN in_IN visual_JJ reactivity_NN
          (_( ΔCBF_NN 
          react_VB )_) between_IN the_DT patient_NN and_CC
          control_NN groups_NNS ._.
          Following_VBG acetazolamide_NN at_IN the_DT 20_CD -_: minute_NN time_NN point_NN ,_,
          the_DT rCBF_NN in_IN the_DT control_NN group_NN was_VBD significantly_RB elevated_VBD
          in_IN a_DT more_RBR central_NN and_CC anterior_NN distribution_NN (_( p_NN =_SYM 0_CD ._. 041_CD )_) ,_,
          while_IN the_DT distribution_NN of_IN the_DT higher_JJR rCBF_NN voxels_NNS in_IN the_DT
          Fabry_NNP group_NN was_VBD more_JJR posterior_NN (_( data_NNS not_RB shown_VBN ,_, p_NN =_SYM
          0_CD ._. 002_CD )_) ._. At_IN the_DT 30_CD -_: minute_NN time_NN point_NN the_DT significantly_RB
          elevated_VBD rCBF_NN in_IN the_DT control_NN group_NN had_VBD disappeared_VBN while_IN
          the_DT significantly_RB elevated_VBD rCBF_NN in_IN the_DT Fabry_NNP group_NN
          persisted_VBD (_( Figure_NN 2_CD ,_, p_NN =_SYM 0_CD ._. 003_CD )_) indicating_VBG a_DT prolonged_JJ
          cerebral_JJ vascular_NN response_NN time_NN ._. No_DT difference_NN in_IN
          regional_JJ ΔCBF_NN 
          res_NNS between_IN the_DT Fabry_NNP and_CC control_NN
          groups_NNS was_VBD found_VBN indicating_VBG normal_JJ regional_JJ cerebral_JJ
          vascular_NN reserve_NN in_IN Fabry_NNP disease_NN ._.
          ERT_NNP resulted_VBD in_IN a_DT significantly_RB lower_JJR absolute_JJ rCBF_NN
          during_IN visual_JJ stimulation_NN in_IN the_DT treatment_NN group_NN compared_VBN
          to_TO the_DT placebo_NN (_( Figure_NN 3_CD ,_, p_NN <_NN 0_CD ._. 001_CD )_) while_IN no_DT
          significantly_RB decreased_VBN areas_NNS of_IN rCBF_NN were_VBD found_VBN in_IN the_DT
          placebo_NN group_NN ._. A_DT reduction_NN in_IN rCBF_NN was_VBD also_RB found_VBN when_WRB
          the_DT analysis_NN was_VBD restricted_VBN to_TO the_DT visual_JJ cortex_NN (_( p_NN <_NN
          0_CD ._. 001_CD )_) with_IN no_DT areas_NNS of_IN significantly_RB decreased_VBD rCBF_NN in_IN
          the_DT placebo_NN group_NN ._. ERT_NNP led_VBD to_TO decreased_VBD rCBF_NN after_IN
          acetazolamide_NN infusion_NN at_IN both_DT time_NN points_NNS (_( time_NN =_SYM 20_CD
          minutes_NNS ,_, p_NN <_NN 0_CD ._. 001_CD ,_, time_NN =_SYM 30_CD minutes_NNS ,_, p_NN =_SYM 0_CD ._. 004_CD ,_,
          Figure_NN 4_LS )_) ._. No_DT significant_JJ decrease_NN in_IN rCBF_NN was_VBD found_VBN at_IN a_DT
          comparable_JJ cluster_NN extent_NN and_CC voxel_NN threshold_NN in_IN the_DT
          placebo_NN group_NN ._.
        
      
      
        Discussion_NNP
        Our_PRP$ data_NNS indicate_VBP the_DT presence_NN of_IN an_DT abnormal_JJ functional_JJ
        response_NN to_TO visual_JJ stimulation_NN both_DT in_IN global_JJ and_CC regional_JJ
        CBF_NNP analysis_NN in_IN Fabry_NNP disease_NN ._. This_DT however_RB was_VBD not_RB due_JJ to_TO
        an_DT alteration_NN in_IN vascular_NN reactivity_NN ._. Previously_RB ,_, we_PRP
        demonstrated_VBD that_IN the_DT resting_VBG rCBF_NN in_IN Fabry_NNP disease_NN is_VBZ
        elevated_VBD compared_VBN to_TO controls_NNS particularly_RB in_IN the_DT posterior_NN
        circulation_NN [_NN 5_CD ]_NN ._. In_IN view_NN of_IN the_DT normal_JJ visual_JJ area_NN
        reactivity_NN in_IN Fabry_NNP disease_NN ,_, these_DT findings_NNS indicate_VBP that_IN
        the_DT Fabry_NNP group_NN response_NN to_TO visual_JJ activation_NN is_VBZ largely_RB
        explained_VBN by_IN the_DT elevated_VBD resting_VBG rCBF_NN ._. However_RB ,_, the_DT more_RBR
        generalized_JJ cerebrovascular_NN response_NN noted_VBD in_IN both_DT the_DT
        carotid_NN and_CC vertebro-basilar_JJ circulation_NN suggests_VBZ stimulus_NN
        spread_VBD in_IN Fabry_NNP disease_NN ,_, possibly_RB due_JJ to_TO a_DT decreased_VBN
        response_NN threshold_NN in_IN non-visual_JJ cortex_NN vasculature_NN ._.
        Following_VBG ERT_NNP ,_, this_DT resting_VBG rCBF_NN abnormality_NN was_VBD reversed_VBN [_NN
        5_CD ]_NN ._.
        The_DT cerebral_JJ visual_JJ stimulation_NN paradigm_NN used_VBN in_IN the_DT
        current_JJ study_NN is_VBZ known_VBN to_TO induce_VB maximal_NN cerebral_JJ blood_NN
        flow_NN [_NN 12_CD ]_NN and_CC is_VBZ therefore_RB a_DT useful_JJ stimulus_NN for_IN the_DT
        study_NN of_IN neuro-vascular_JJ coupling_NN ._. Visual_NNP stimulation_NN was_VBD
        chosen_VBN in_IN particular_JJ because_IN of_IN the_DT known_VBN predilection_NN of_IN
        the_DT cerebrovascular_NN abnormalities_NNS in_IN Fabry_NNP disease_NN for_IN the_DT
        posterior_NN circulation_NN [_NN 7_CD 10_CD ]_NN ._. The_DT lack_NN of_IN an_DT increase_NN or_CC
        decrease_VB in_IN visual_JJ rCBF_NN reactivity_NN in_IN Fabry_NNP disease_NN
        suggests_VBZ normal_JJ neuro-vascular_JJ coupling_NN mechanism_NN [_NN 18_CD 19_CD ]_NN
        ._.
        Acetazolamide-induced_NNP maximal_NN cerebral_JJ vasodilatory_NN
        response_NN is_VBZ often_RB used_VBN to_TO assess_VB cerebrovascular_NN reserve_NN [_NN
        20_CD ]_NN ._. The_DT greatest_JJS difference_NN between_IN our_PRP$ patients_NNS and_CC
        controls_NNS occurred_VBD at_IN the_DT 30_CD -_: minute_NN time_NN point_NN rather_RB than_IN
        at_IN the_DT 20_CD -_: minute_NN time_NN point_NN of_IN the_DT acetazolamide_NN challenge_NN ._.
        This_DT finding_VBG is_VBZ consistent_JJ with_IN a_DT prolongation_NN of_IN the_DT
        cerebral_JJ vascular_NN response_NN time_NN in_IN the_DT Fabry_NNP disease_NN ._. ERT_NNP
        significantly_RB decreased_VBD the_DT prolonged_JJ cerebral_JJ vascular_NN
        response_NN time_NN ._. The_DT vasodilator_NN effect_NN of_IN acetazolamide_NN on_IN
        the_DT cerebral_JJ vasculature_NN has_VBZ been_VBN characterized_VBN by_IN both_DT PET_NNP
        and_CC transcranial_NN Doppler_NNP (_( TCD_NNP )_) studies_NNS [_NN 21_CD 22_CD ]_NN ._. At_IN a_DT
        dose_NN of_IN 15_CD mg_NN /_NN kg_NN the_DT effect_NN of_IN acetazolamide_NN is_VBZ thought_VBN to_TO
        be_VB supramaximal_NN with_IN maximal_NN cerebral_JJ vasodilation_NN induced_VBN
        within_IN about_IN 20_CD minutes_NNS ._. By_IN TCD_NNP a_DT maximal_NN dose-response_JJ was_VBD
        found_VBN to_TO occur_VB with_IN an_DT acetazolamide_NN infusion_NN of_IN between_IN 15_CD
        and_CC 18_CD mg_NN /_NN kg_NN with_IN maximal_NN vasoreactivity_NN occurring_VBG between_IN
        10_CD and_CC 30_CD minutes_NNS post_NN acetazolamide_NN [_NN 21_CD ]_NN ._. Using_VBG [_NN 15_CD O_NNP ]_NN H_NNP
        
        2_LS O_NNP and_CC PET_NNP ,_, a_DT further_JJ study_NN of_IN rCBF_NN
        following_VBG 1_CD g_SYM of_IN acetazolamide_NN demonstrated_VBD the_DT peak_NN
        response_NN to_TO occur_VB at_IN 10_CD minutes_NNS while_IN the_DT plateau_NN phase_NN
        occurred_VBD during_IN the_DT twenty_CD to_TO thirty_CD minute_NN time_NN period_NN
        post_NN acetazolamide_NN [_NN 22_CD ]_NN ._. The_DT measurements_NNS in_IN the_DT current_JJ
        study_NN obtained_VBN at_IN twenty_CD and_CC thirty_CD minutes_NNS post_NN
        acetazolamide_NN injection_NN therefore_RB ,_, probably_RB corresponds_NNS to_TO
        the_DT plateau_NN phase_NN of_IN reported_JJ acetazolamide_NN responses_NNS ._.
        The_DT CBF_NNP response_NN to_TO supra-maximal_JJ acetazolamide_NN
        challenge_NN consists_VBZ of_IN a_DT phase_NN of_IN increasing_VBG CBF_NNP followed_VBN by_IN
        a_DT plateau_NN phase_NN with_IN a_DT terminal_NN recovery_NN phase_NN ._. This_DT can_MD be_VB
        considered_VBN in_IN terms_NNS of_IN cerebrovascular_NN resistance_NN and_CC
        capacity_NN ,_, analogous_JJ to_TO a_DT high_JJ pass_NN filter_NN where_WRB high_JJ
        frequency_NN components_NNS of_IN the_DT system_NN response_NN are_VBP removed_VBN ._.
        The_DT importance_NN of_IN this_DT analogy_NN is_VBZ that_IN the_DT plateau_NN response_NN
        is_VBZ dependent_JJ on_IN both_DT the_DT system_NN 's_POS resistive_JJ and_CC
        capacitative_JJ components_NNS ._. In_IN the_DT present_JJ study_NN it_PRP was_VBD seen_VBN
        that_IN the_DT vasomotor_NN reserve_NN in_IN Fabry_NNP disease_NN was_VBD within_IN
        normal_JJ limits_NNS despite_IN the_DT elevated_VBD resting_VBG rCBF_NN ._. The_DT
        cerebrovascular_NN capacity_NN in_IN Fabry_NNP disease_NN was_VBD also_RB within_IN
        normal_JJ limits_NNS ,_, suggesting_VBG absence_NN of_IN clinically_RB significant_JJ
        vaso-occlusive_JJ disease_NN in_IN the_DT cohort_NN of_IN Fabry_NNP patients_NNS
        examined_VBD ._. This_DT finding_VBG is_VBZ supported_VBN by_IN the_DT absence_NN of_IN
        abnormalities_NNS on_IN magnetic_JJ resonance_NN angiography_NN in_IN the_DT same_JJ
        group_NN ._. Reduced_NNP ΔCBF_NN 
        res_NNS would_MD be_VB expected_VBN when_WRB the_DT resistive_JJ
        component_NN is_VBZ increased_VBN reducing_VBG the_DT amplitude_NN of_IN the_DT
        acetazolamide_NN induced_VBD plateau_NN response_NN ._.
        The_DT hyperemic_JJ cerebrovascular_NN response_NN to_TO hypercapnia_NN or_CC
        acetazolamide_NN is_VBZ not_RB inhibited_VBD by_IN nitric_JJ oxide_NN synthase_NN
        inhibitors_NNS such_JJ as_IN 
        N_NNP G-_NNP monomethyl-_NN L-_NNP arginine_NN (_( L-NMMA_NNP )_)
        suggesting_VBG that_IN NO_DT does_VBZ not_RB mediate_VB vasoreactivity_NN [_NN 23_CD 24_CD
        ]_NN ._. The_DT mechanism_NN of_IN acetazolamide_NN vasodilation_NN ,_, beyond_IN
        smooth_JJ muscle_NN intracellular_NN and_CC extracellular_NN acidosis_NNS due_JJ
        carbonic_JJ anhydrase_NN inhibition_NN ,_, is_VBZ unclear_JJ ._. Abnormalities_NNP of_IN
        the_DT peripheral_JJ vasculature_NN responses_NNS to_TO acetylcholine_NN have_VBP
        been_VBN previously_RB described_VBN in_IN Fabry_NNP disease_NN together_RB with_IN
        nitric_JJ oxide_NN pathway_NN dysregulation_NN [_NN 5_CD 9_CD ]_NN suggesting_VBG
        participation_NN of_IN non-_NN NO_DT regulation_NN of_IN vascular_NN tone_NN ._. A_DT
        similar_JJ vascular_NN hyper-responsiveness_JJ has_VBZ been_VBN noted_VBN in_IN
        caveolin-_NN 1_CD knock-out_JJ mice_NNS [_NN 25_CD 26_CD ]_NN raising_VBG the_DT possibility_NN
        that_IN the_DT accumulation_NN of_IN Gb_NNP 
        3_CD results_NNS in_IN over-activity_JJ of_IN uncoupled_JJ
        endothelial_NN nitric_JJ oxide_NN synthase_NN within_IN endothelial_NN cell_NN
        caveolae_NN generating_NN superoxide_NN and_CC other_JJ reactive_JJ oxygen_NN
        species_NNS [_NN 27_CD ]_NN ._. The_DT latter_JJ may_MD have_VB a_DT vasodilatatory_NN
        effect_NN [_NN 28_CD ]_NN ._. Predominance_NNP of_IN vascular_NN abnormalities_NNS in_IN
        the_DT vertebro-basilar_JJ system_NN in_IN Fabry_NNP disease_NN suggests_VBZ
        fundamental_JJ biologic_JJ differences_NNS between_IN the_DT anterior_NN and_CC
        the_DT posterior_NN circulation_NN ._. Such_JJ difference_NN might_MD ,_, for_IN
        example_NN ,_, result_NN from_IN the_DT neural_NN crest_NN origin_NN of_IN pericytes_NNS
        and_CC vascular_NN smooth_JJ muscle_NN in_IN the_DT anterior_NN circulation_NN as_IN
        opposed_VBN to_TO paraxial_NN mesoderm_NN in_IN the_DT vertebro-basilar_JJ or_CC
        posterior_NN circulation_NN [_NN 29_CD ]_NN ._.
      
      
        Conclusion_NNP
        The_DT current_JJ study_NN indicates_VBZ that_IN ERT_NNP normalized_JJ
        acetazolamide-induced_JJ prolonged_JJ cerebral_JJ vascular_NN response_NN
        time_NN in_IN Fabry_NNP disease_NN ._. This_DT finding_VBG suggests_VBZ that_IN the_DT
        underlying_VBG abnormality_NN is_VBZ present_JJ at_IN the_DT luminal_NN side_NN of_IN
        the_DT blood-brain_JJ barrier_NN (_( BBB_NNP )_) complex_JJ and_CC is_VBZ due_JJ to_TO an_DT
        abnormality_NN of_IN the_DT cerebral_JJ vessels_NNS since_IN it_PRP is_VBZ unlikely_JJ
        that_IN α-galactosidase_JJ A_DT crosses_VBZ the_DT BBB_NNP to_TO any_DT appreciable_JJ
        extent_NN ._. Further_RB ,_, the_DT treatment_NN effect_NN appeared_VBD to_TO be_VB
        uniform_NN across_IN all_DT cerebral_JJ vascular_NN distributions_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD
      
      
        Authors_NNP '_'' contributions_NNS
        DFM_NNP carried_VBD out_IN and_CC coordinated_VBN the_DT PET_NNP studies_NNS ,_,
        performed_VBD the_DT data_NNS and_CC statistical_JJ analysis_NN and_CC drafted_VBD the_DT
        manuscript_NN ._. GA_NNP contributed_VBD to_TO carrying_VBG out_RP the_DT PET_NNP studies_NNS
        and_CC drafting_VBG of_IN the_DT manuscript_NN ._. PH_NNP participated_VBD in_IN the_DT
        design_NN of_IN the_DT study_NN and_CC drafting_VBG the_DT manuscript_NN ._. RS_NNP
        conceived_VBD of_IN the_DT study_NN and_CC participated_VBD in_IN its_PRP$ design_NN and_CC
        co-ordination_JJ together_RB with_IN drafting_VBG the_DT manuscript_NN ._.
      
    
  
